Xtant Medical FY25 net income rises to $5 million; revenue increases 14% to $134 million

Reuters04-01

Xtant Medical FY25 net income rises to $5 million; revenue increases 14% to $134 million

Xtant Medical posted full-year 2025 net income of USD 5 million, reversing a USD 16.5 million net loss.
Revenue rose 14% to USD 134 million.
Adjusted EBITDA climbed to USD 16.3 million from an adjusted EBITDA loss.
Cash totaled USD 17.3 million at Dec. 31, 2025, with an additional USD 10.5 million received after year-end tied to the Companion Spine divestiture.
Recent updates included sale of non-core Coflex and CoFix assets and international hardware businesses to Companion Spine for USD 21.4 million in cash, alongside commercial launches of nanOss Strata synthetic bone graft and CollagenX wound-closure product.
2026 revenue guidance was set at USD 95 million to USD 99 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603310700PR_NEWS_USPR_____LA23144) on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624553346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624553346","market":"us","top_or_hot":-1,"title":"Xtant Medical FY25 net income rises to $5 million; revenue increases 14% to $134 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xtant Medical FY25 net income rises to $5 million; revenue increases 14% to $134 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Xtant Medical posted full-year 2025 net income of USD 5 million, reversing a USD 16.5 million net loss.\n        </li>\n<li>\n          Revenue rose 14% to USD 134 million.\n        </li>\n<li>\n          Adjusted EBITDA climbed to USD 16.3 million from an adjusted EBITDA loss.\n        </li>\n<li>\n          Cash totaled USD 17.3 million at Dec. 31, 2025, with an additional USD 10.5 million received after year-end tied to the Companion Spine divestiture.\n        </li>\n<li>\n          Recent updates included sale of non-core Coflex and CoFix assets and international hardware businesses to Companion Spine for USD 21.4 million in cash, alongside commercial launches of nanOss Strata synthetic bone graft and CollagenX wound-closure product.\n        </li>\n<li>\n          2026 revenue guidance was set at USD 95 million to USD 99 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XTNT\">Xtant Medical Holdings Inc</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603310700PR_NEWS_USPR_____LA23144) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xtant Medical FY25 net income rises to $5 million; revenue increases 14% to $134 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXtant Medical FY25 net income rises to $5 million; revenue increases 14% to $134 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xtant Medical FY25 net income rises to $5 million; revenue increases 14% to $134 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Xtant Medical posted full-year 2025 net income of USD 5 million, reversing a USD 16.5 million net loss.\n        </li>\n<li>\n          Revenue rose 14% to USD 134 million.\n        </li>\n<li>\n          Adjusted EBITDA climbed to USD 16.3 million from an adjusted EBITDA loss.\n        </li>\n<li>\n          Cash totaled USD 17.3 million at Dec. 31, 2025, with an additional USD 10.5 million received after year-end tied to the Companion Spine divestiture.\n        </li>\n<li>\n          Recent updates included sale of non-core Coflex and CoFix assets and international hardware businesses to Companion Spine for USD 21.4 million in cash, alongside commercial launches of nanOss Strata synthetic bone graft and CollagenX wound-closure product.\n        </li>\n<li>\n          2026 revenue guidance was set at USD 95 million to USD 99 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XTNT\">Xtant Medical Holdings Inc</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603310700PR_NEWS_USPR_____LA23144) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL5hz3CM:1","article_id":"2624553346","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624553346","pubTimestamp":1774991245,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xtant Medical posted full-year 2025 net income of USD 5 million, reversing a USD 16.5 million net loss.Adjusted EBITDA climbed to USD 16.3 million from an adjusted EBITDA loss.Cash totaled USD 17.3 million at Dec. 31, 2025, with an additional USD 10.5 million received after year-end tied to the Companion Spine divestiture.Recent updates included sale of non-core Coflex and CoFix assets and international hardware businesses to Companion Spine for USD 21.4 million in cash, alongside commercial launches of nanOss Strata synthetic bone graft and CollagenX wound-closure product.2026 revenue guidance was set at USD 95 million to USD 99 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","XTNT":"Xtant Medical Holdings Inc"},"translate_title":"Xtant Medical 2025财年净利润升至500万美元；收入增长14%至1.34亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XTNT":0.9},"content_text":"Xtant Medical FY25 net income rises to $5 million; revenue increases 14% to $134 million\n    \n\n\n          Xtant Medical posted full-year 2025 net income of USD 5 million, reversing a USD 16.5 million net loss.\n        \n\n          Revenue rose 14% to USD 134 million.\n        \n\n          Adjusted EBITDA climbed to USD 16.3 million from an adjusted EBITDA loss.\n        \n\n          Cash totaled USD 17.3 million at Dec. 31, 2025, with an additional USD 10.5 million received after year-end tied to the Companion Spine divestiture.\n        \n\n          Recent updates included sale of non-core Coflex and CoFix assets and international hardware businesses to Companion Spine for USD 21.4 million in cash, alongside commercial launches of nanOss Strata synthetic bone graft and CollagenX wound-closure product.\n        \n\n          2026 revenue guidance was set at USD 95 million to USD 99 million.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603310700PR_NEWS_USPR_____LA23144) on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624553346","isCrawlerRequest":true}